Skip to content

A reverse stock split has helped Boulder-based Brickell Biotech Inc. (Nasdaq: BBI) regain compliance with the Nasdaq stock market and avoid delisting.

Brickell said Wednesday that it had received formal notice from Nasdaq that it had regained compliance with the minimum-bid-price requirement for continued listing.

A hearing that was scheduled to review its listing has been canceled, and “Brickell’s common stock will continue to be listed and traded on Nasdaq,” the company said.

Brickell received a delisting notice from Nasdaq in June because its stock price had dropped below the minimum threshold of $1 for more than 30 consecutive days.

Brickell requested a hearing on the delisting and in the meantime scheduled a shareholders meeting to consider a 1-for-45 reverse stock split.

Shareholders approved the reverse stock split June 30, and the stock split became effective July 5.

The 1-for-45 reverse stock split reduced the number of outstanding shares of Brickell common stock from about 121.1 million shares to about 2.7 million shares.

Brickell’s stock closed up 9.5% Wednesday at $3.23 per share, up 28 cents.

This article was first published by BizWest, an independent news organization, and is published under a license agreement. © 2022 BizWest Media LLC.

Join the Conversation

We invite you to use our commenting platform to engage in insightful conversations about issues in our community. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable to us, and to disclose any information necessary to satisfy the law, regulation, or government request. We might permanently block any user who abuses these conditions.